

10/583,046M\_S\_partial scope Yong Chu 09/22/2009

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS	4	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS	5	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS	6	JUN 29	EPFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields
NEWS	7	JUL 09	PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS	8	JUL 14	USGENE enhances coverage of patent sequence location (PSL) data
NEWS	9	JUL 27	CA/CAPLUS enhanced with new citing references
NEWS	10	JUL 16	GBFULL adds patent backfile data to 1855
NEWS	11	JUL 21	USGENE adds bibliographic and sequence information
NEWS	12	JUL 28	EPFULL adds first-page images and applicant-cited references
NEWS	13	JUL 28	INPADOCDB and INPAFAMDB add Russian legal status data
NEWS	14	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	15	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	16	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	17	AUG 24	CA/CAPLUS enhanced with legal status information for U.S. patents
NEWS	18	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	19	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial

products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:01:31 ON 21 SEP 2009

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 11:01:46 ON 21 SEP 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 SEP 2009 HIGHEST RN 1185847-75-9

DICTIONARY FILE UPDATES: 20 SEP 2009 HIGHEST RN 1185847-75-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Documents and Settings\ychu\Desktop\Case\10583046\L15\_09222009.str



chain nodes :

1 2 3 4 5 7 8 9 13 14

chain bonds :

1-2 2-3 3-4 3-5 4-7 7-8 8-9 8-13 9-14

exact/norm bonds :

1-2 2-3 3-4 3-5 4-7 8-9 8-13 9-14

exact bonds :

7-8

Connectivity :

5:1 E exact RC ring/chain 13:1 E exact RC ring/chain  
Match level :  
1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 7:CLASS 8:CLASS 9:Atom 13:CLASS  
14:Atom

Generic attributes :

1:  
Saturation : Unsaturated

Element Count :

Node 9: Limited

N,N1

Node 14: Limited


N,N1

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:02:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 13725 TO ITERATE

14.6% PROCESSED 2000 ITERATIONS

6 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*


PROJECTED ITERATIONS: 267480 TO 281520

PROJECTED ANSWERS: 438 TO 1208

L2 6 SEA SSS SAM L1

=> d scan

L2 6 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C27 H33 N5 O5 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> s l1 full

FULL SEARCH INITIATED 11:18:37 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 276530 TO ITERATE

100.0% PROCESSED 276530 ITERATIONS 682 ANSWERS  
SEARCH TIME: 00.00.06

L3 682 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	199.32	199.54

FILE 'CAPLUS' ENTERED AT 11:18:52 ON 21 SEP 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Sep 2009 VOL 151 ISS 13  
FILE LAST UPDATED: 20 Sep 2009 (20090920/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAPLUS family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> s l3

L4 20 L3

=> d ibib abs hitstr tot

THE ESTIMATED COST FOR THIS REQUEST IS 112.80 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L4 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:288826 CAPLUS Full-text

DOCUMENT NUMBER: 150:330127

TITLE: Preparation of biphenyls and biheteroaryls end-capped with amino acid or peptide derivatives as hepatitis c virus inhibitors

INVENTOR(S): Bachand, Carol; Belema, Makonen; Deon, Daniel H.; Good, Andrew C.; Goodrich, Jason; James, Clint A.; Lavoie, Rico; Lopez, Omar D.; Martel, Alain; Meanwell, Nicholas A.; Nguyen, Van N.; Romine, Jeffrey Lee; Ruediger, Edward H.; Snyder, Lawrence B.; St. Laurent, Denis R.; Yang, Fukang; Langley, David R.; Wang, Gan; Hamann, Lawrence G.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: U.S. Pat. Appl. Publ., 515pp., Cont.-in-part of U.S. Ser. No. 835,462.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 20090068140	A1	20090312	US 2008-30232	20080213
US 20080050336	A1	20080228	US 2007-835462	20070808
PRIORITY APPLN. INFO.:			US 2007-835462	A2 20070808
			US 2006-836996P	P 20060811
OTHER SOURCE(S):			MARPAT 150:330127	
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention is related to 4,4'-disubstituted biphenyls and biheteroaryls in which the substituents in 4 and 4' positions contain structures assocd. with amino acids and peptides, e.g., I, their pharmaceutical acceptable salts, pharmaceutical compns. and methods for the treatment of hepatitis C virus (HCV) infection. Thus, Pd-coupling of bromide II (prepn. given) with boronate III (prepn. given), hydrogenolysis, cleavage of the tert-butoxycarbonyl groups and coupling with N-(methoxycarbonyl)-L-valine gave I as an acetate salt. Compds. of the invention were active in an HCV replicon assay.

IT 1009113-10-3P

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; prepn. of biphenyls and biheteroaryls end-capped with amino acid or peptide derivs. as hepatitis c virus inhibitors)

RN 1009113-10-3 CAPLUS


CN Urea, N-[(1R)-2-oxo-1-phenyl-2-[(2S)-2-[5-[4'-[2-[(2S)-1-[(2R)-tetrahydro-2-furanyl]carbonyl]-2-pyrrolidinyl]-1H-imidazol-5-yl][1,1'-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]ethyl]-N'-3-pyridinyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



ACCESSION NUMBER: 2008:220741 CAPLUS Full-text  
 DOCUMENT NUMBER: 148:308634  
 TITLE: Preparation of biphenyls and biheteroaryls end-capped with amino acid or peptide derivatives as hepatitis c virus inhibitors  
 INVENTOR(S): Bachand, Carol; Belema, Makonen; Deon, Daniel H.; Good, Andrew C.; Goodrich, Jason; James, Clint A.; Lavoie, Rico; Lopez, Omar D.; Martel, Alain; Meanwell, Nicholas A.; Nguyen, Van N.; Romine, Jeffrey Lee; Ruediger, Edward H.; Snyder, Lawrence B.; St. Laurent, Denis R.; Yang, Fukang; Langley, David R.; Wang, Gan; Hamann, Lawrence G.  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 732pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008021927	A2	20080221	WO 2007-US75544	20070809
WO 2008021927	A3	20080529		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA US 20080050336 A1 20080228 US 2007-835462 20070808 AU 2007286222 A1 20080221 AU 2007-286222 20070809 CA 2660520 A1 20080221 CA 2007-2660520 20070809 EP 2049522 A2 20090422 EP 2007-800058 20070809 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS NO 2009000447 A 20090302 NO 2009-447 20090129 IN 2009DN00853 A 20090612 IN 2009-DN853 20090205 KR 2009040909 A 20090427 KR 2009-704970 20090310 PRIORITY APPLN. INFO.: US 2006-836996P P 20060811 US 2007-835462 A 20070808 WO 2007-US75544 W 20070809 OTHER SOURCE(S): MARPAT 148:308634 GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention is related to 4,4'-disubstituted biphenyls and biheteroaryls in which the substituents in 4 and 4' positions contain structures assocd. with amino acids and peptides, e.g. I, their pharmaceutical acceptable salts,

pharmaceutical compns. and methods for the treatment of hepatitis C virus (HCV) infection. Thus, Pd-coupling of bromide II (prepn. given) with boronate III (prepn. given), hydrogenolysis, cleavage of the tert-butoxycarbonyl groups and coupling with N-(methoxycarbonyl)-L-valine gave I as an acetate salt. Compds. of the invention were active in an HCV replicon assay.

IT 1009113-10-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; prepn. of biphenyls and biheteroaryls end-capped with amino acid or peptide derivs. as hepatitis c virus inhibitors)

RN 1009113-10-3 CAPLUS

CN Urea, N-[(1R)-2-oxo-1-phenyl-2-[(2S)-2-[5-[4'-[2-[(2S)-1-[(2R)-tetrahydro-2-furanyl]carbonyl]-2-pyrrolidinyl]-1H-imidazol-5-yl][1,1'-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pyrrolidinyl]ethyl]-N'-3-pyridinyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





TITLE: Preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists for treating migraine and other conditions

INVENTOR(S): Chen, Ling; Chaturvedula, Prasad V.; Civiello, Rita; Degnan, Andrew P.; Dubowchik, Gene M.; Han, Xiaojun; Jiang, Xiang Jun J.; Karageorge, George N.; Luo, Guanglin; Macor, John E.; Poindexter, Graham S.; Tora, George O.

PATENT ASSIGNEE(S): ~~Bristol-Myers Squibb Company, USA~~

SOURCE: U.S. Pat. Appl. Publ., 215pp., Cont.-in-part of U.S. Ser. No. 729,155.  
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070232600	A1	20071004	US 2007-620291	20070105
US 7314883	B2	20080101		
US 20040204397	A1	20041014	US 2003-729155	20031205
US 7220862	B2	20070522		

PRIORITY APPLN. INFO.:

US 2003-729155	A2	20031205
US 2002-386138P	P	20020605
US 2002-388617P	P	20020613
US 2002-389870P	P	20020619
US 2002-393200P	P	20020701
US 2002-413534P	P	20020925
US 2003-445523	A2	20030527

OTHER SOURCE(S): MARPAT 147:406845

GI



AB Diazaheterocycles I [m, n = 0-2; V = (un)substituted NH<sub>2</sub>, OH; Q = (un)substituted alkyl, NH<sub>2</sub>, NHCO<sub>2</sub>H, NHCONH<sub>2</sub>; U = CH<sub>2</sub>, NH; D = O, NCN, alkylsulfonylimino; A = C, N, CH; E = (un)substituted heterocyclic; with provisos] were prepd. for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic

inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing assocd. with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Thus, the indazole II was prepd. from 1H-indazole-5-carboxaldehyde and had IC50 for calcitonin gene related peptide receptor binding of .1toreq. 10 nM.

IT 635711-71-6P 635711-72-7P 635711-73-8P  
 635711-75-0P 635711-76-1P 635711-77-2P  
 635711-78-3P 635711-79-4P 635711-80-7P  
 635711-82-9P 635711-83-0P 635711-84-1P  
 635711-86-3P 635711-87-4P 635711-88-5P  
 635711-89-6P 635711-90-9P 635711-92-1P  
 635711-93-2P 635711-94-3P 635711-95-4P  
 635711-96-5P 635711-97-6P 635711-98-7P  
 635711-99-8P 635712-00-4P 635712-01-5P  
 635712-02-6P 635712-04-8P 635712-05-9P  
 635712-08-2P 635712-09-3P 635712-10-6P  
 635712-11-7P 635712-12-8P 635712-13-9P  
 635712-14-0P 635712-15-1P 635712-16-2P  
 635712-17-3P 635712-19-5P 635712-20-8P  
 635712-22-0P 635712-23-1P 635712-24-2P  
 635712-25-3P 635712-26-4P 635712-27-5P  
 635712-28-6P 635712-29-7P 635712-30-0P  
 635712-31-1P 635712-32-2P 635712-33-3P  
 635712-34-4P 635712-35-5P 635712-38-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of diazaheterocycles as calcitonin gene related peptide receptor antagonists for treating migraine and other diseases)

RN 635711-71-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-2-naphthalenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-72-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-73-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-1-naphthalenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-75-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4,5-trimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-76-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-77-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-78-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-79-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-80-7 CAPLUS

CN Urea, N-[1,1'-biphenyl]-4-yl-N'-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-82-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-83-0 CAPLUS

CN Urea, N-(3-acetylphenyl)-N'-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-84-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dichlorophenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-86-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-87-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 635711-88-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-89-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-90-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-92-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-93-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-difluorophenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-94-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethylphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-95-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,4-dimethylphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-96-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dichlorophenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-97-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-98-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-99-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-00-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-difluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-01-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-dichloro-4-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-02-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-04-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[2-chloro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-05-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3,4-trifluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 635712-08-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-09-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-10-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dichlorophenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-11-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethoxyphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-12-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-13-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-14-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-15-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-16-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-17-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-19-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-20-8 CAPLUS

CN Benzoic acid, 4-[[[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-22-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-difluorophenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-23-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethylphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-24-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-25-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 635712-26-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-chloro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-27-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-28-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-29-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-30-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-31-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-32-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromo-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-33-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-fluoro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-34-4 CAPLUS

CN Benzoic acid, 3-[[[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-35-5 CAPLUS

CN Urea, N-[1,1'-biphenyl]-2-yl-N'--[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-38-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 119 THERE ARE 119 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:845275 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 147:227208

TITLE: Compositions and methods using matrix metalloproteinase (MMP) inhibitors for treating cognitive impairment characterized by persistent or sustained MMP expression and/or activity

INVENTOR(S): Harding, Joseph; Wright, John; Meighan, Peter; Meighan, Stala

PATENT ASSIGNEE(S): Washington State University Research Foundation, USA

SOURCE: PCT Int. Appl., 92pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007087637	A2	20070802	WO 2007-US61167	20070126
WO 2007087637	A3	20071129		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-762388P P 20060126

AB The invention provides methods for treating cognitive impairment, comprising administration of a therapeutically effective amt. of at least one matrix metalloproteinase (MMP) inhibitor sufficient to provide for at least one of precluding, alleviating, reversing, or inhibiting cognitive impairment characterized by sustained elevated expression and/or activity of at least one MMP. Persistent elevations in the expression of MMPs in the hippocampus of aged individuals have a detrimental effect on hippocampal synaptic plasticity, and are an underlying cause of cognitive deficits assocd. with ageing, and particular aspects therefore provide novel compns. and methods comprising use of MMP (e.g., MMP3 and/or MMP9, etc.) inhibitors to treat age-related cognitive impairment (e.g., cognitive decline). Addnl. embodiments comprise inhibition of MMP-3 and at least one other MMP (e.g., MMP-9, etc). Exemplary MMP inhibitors comprise a zinc-binding hydroxamate moiety (or a non-hydroxamate zinc-binding moiety), and a peptide or peptidomimetic backbone capable of binding at least one MMP.

IT 198700-71-9


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(matrix metalloproteinase inhibitors for treating cognitive impairment, and use with other agents)

RN 198700-71-9 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-[(1S)-2-oxo-1-(phenylmethyl)-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




L4 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2007:705719 CAPLUS Full-text  
 DOCUMENT NUMBER: 147:118256  
 TITLE: Preparation of piperidine-1-carboxamide derivatives and spirocycles thereof as antagonists of calcitonin gene-related peptide receptors  
 INVENTOR(S): Chaturvedula, Prasad V.; Chen, Ling; Civiello, Rita; Degnan, Andrew P.; Dubowchik, Gene M.; Han, Xiaojun; Jiang, Xiang Jun J.; Macor, John E.; Poindexter, Graham S.; Tora, George O.; Luo, Guanglin  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: ~~U.S. Pat. Appl. Publ., 198pp., Cont.-in-part of U.S. Ser. No. 729,155.~~  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070149503	A1	20070628	US 2007-620308	20070105
US 20040204397	A1	20041014	US 2003-729155	<u>20031205</u>
US 7220862	B2	20070522		

PRIORITY APPLN. INFO.:

US 2003-729155	A2	20031205
US 2002-386138P	P	20020605
US 2002-388617P	P	20020613
US 2002-389870P	P	20020619
US 2002-393200P	P	20020701
US 2002-413534P	P	20020925
US 2003-445523	A2	20030527

OTHER SOURCE(S): MARPAT 147:118256  
 GI



AB The title compds. [I; V = N(R1)(R2) or OR4; R4 = H, C1-6 alkyl, C1-4 haloalkyl, etc.; R1, R2 = independently H, each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -C1-6alkyleneamino(C1-3alkyl)2, C3-7 cycloalkyl,



Ph, azetidiny, adamantyl, tetrahydrofuranyl, furanyl, dioxolanyl, thienyl, tetrahydrothienyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, etc.; R1 and R2 optionally and independently contain 1 or 2 carbonyls or optionally and independently interrupted from the nitrogen to which C1-3 alkylene or C1-3 alkylidene; or NR1R2 together form each (un)substituted azetidiny, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, azepinyl, or diazepinyl, or spirocyclic ring, etc.; Q = (Sy)sR3, NH(Sy)sR3, NHC(O)(Sy)sR3, NHC(O)O(Sy)sR3, NHC(O)NH(Sy)sR3, O(Sy)sR3, (Sy)sNHR3, etc.; wherein Sy = C1-3 alkylene or C1-3 alkylidene; s = 0 or 1; U = CH2, NH; R3 = (i) heterocycle having two 5 to 7 membered fused rings, (ii) 4 to 6 membered heterocycle contg. 1-3 heteroatoms selected from O, N and S optionally contg. 1 to 2 carbonyls, (iii) C3-7 cycloalkyl, etc.; D = O, N(CN) or N(SO2-C1-3 alkyl); A = C; m, n = 1; E = N, CH, C; p = 0; G, J and E together form a fused heterocycle having two 5- to 7-membered fused rings optionally contg. 1 or 2 carbonyls] or pharmaceutically acceptable salts thereof are prepd. These compds. are antagonists of calcitonin gene-related peptide receptors (CGRP receptor) and are useful in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing assocd. with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors. Thus, (R)-2-[[[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)piperidin-1-yl]carbonyl]amino]-3-[1-[[2-(trimethylsilanyl)ethyl]sulfonyl]-1H-indazol-5-yl]propionic acid was condensed with 4-piperidinopiperidine using PyBIOP in CH2Cl2 at room temp. for 16 h followed by treatment with CsF at 80.degree. in MeCN to give (R)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)piperidine-1-carboxylic acid [2-[1,4']bipiperidinyl-1'-yl-1-(1H-indazol-5-ylmethyl)-2-oxoethyl]amide (II). II showed IC50 of .ltoreq.10 nM for inhibiting the binding of [125I]CGRP to homogenate of SK-NMC cells.

IT 635711-71-6P 635711-72-7P 635711-73-8P  
635711-75-0P 635711-76-1P 635711-77-2P  
635711-78-3P 635711-79-4P 635711-80-7P  
635711-82-9P 635711-83-0P 635711-84-1P  
635711-86-3P 635711-87-4P 635711-88-5P  
635711-89-6P 635711-90-9P 635711-92-1P  
635711-93-2P 635711-94-3P 635711-95-4P  
635711-96-5P 635711-97-6P 635711-98-7P  
635711-99-8P 635712-00-4P 635712-01-5P  
635712-02-6P 635712-04-8P 635712-05-9P  
635712-08-2P 635712-09-3P 635712-10-6P  
635712-11-7P 635712-12-8P 635712-13-9P  
635712-14-0P 635712-15-1P 635712-16-2P  
635712-17-3P 635712-19-5P 635712-20-8P  
635712-22-0P 635712-23-1P 635712-24-2P  
635712-25-3P 635712-26-4P 635712-27-5P  
635712-28-6P 635712-29-7P 635712-30-0P  
635712-31-1P 635712-32-2P 635712-33-3P  
635712-34-4P 635712-35-5P 635712-38-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperidine-1-carboxamide derivs. and spirocyclic compds. thereof as antagonists of calcitonin gene-related peptide receptors)

RN 635711-71-6 CAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin)-1'-ylcarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-2-naphthalenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-72-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-73-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-1-naphthalenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-75-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4,5-trimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-76-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-77-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-78-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-79-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-80-7 CAPLUS

CN Urea, N-[1,1'-biphenyl]-4-yl-N'-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-82-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-83-0 CAPLUS

CN Urea, N-(3-acetylphenyl)-N'-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-84-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dichlorophenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-86-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methoxyphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-87-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-88-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dimethylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 635711-89-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-90-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-92-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethoxyphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-93-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-difluorophenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-94-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethylphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-95-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,4-dimethylphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-96-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-97-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-98-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dichlorophenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-99-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-(1-methylethyl)phenyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-00-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-difluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-01-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-dichloro-4-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-02-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-04-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[2-chloro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-05-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3,4-trifluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-08-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-fluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.








RN 635712-11-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-12-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-ethoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 635712-15-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-16-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-17-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-19-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-20-8 CAPLUS

CN Benzoic acid, 4-[[[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-22-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-difluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-23-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethylphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-24-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-methylphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-25-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-26-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-chloro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 635712-27-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-28-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-29-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-30-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-31-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-32-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromo-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-33-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-fluoro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-34-4 CAPLUS

CN Benzoic acid, 3-[[[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-35-5 CAPLUS

CN Urea, N-[1,1'-biphenyl]-2-yl-N'-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-38-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L4 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:1157062 CAPLUS Full-text  
 DOCUMENT NUMBER: 145:465769  
 TITLE: MMPis for treatment of TGF.beta.-induced subcapsular  
 cataract formation  
 INVENTOR(S): West-Mays, Judith  
 PATENT ASSIGNEE(S): McMaster University, Can.  
 SOURCE: PCT Int. Appl., 47pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006113993	A1	20061102	WO 2006-CA661	20060428
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM CA 2605783 A1 20061102 CA 2006-2605783 20060428 EP 1877051 A1 20080116 EP 2006-721851 20060428 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR US 20080187572 A1 20080807 US 2008-912729 20080311 PRIORITY APPLN. INFO.: US 2005-675443P P 20060428 WO 2006-CA661 W 20060428				

AB The invention provides novel methods and compns. for the treatment and/or prevention of cataracts. A compn. that inhibits destabilization of E-cadherin is administered. Preferably the compn. comprises a matrix metalloproteinase

inhibitor (MMPI). MMPI GM6001 exhibited dose-dependent attenuation of transforming growth factor .beta. (TGF.beta.)-induced cataract formation in an ex vivo rat lens model. The role of MMP-9 in TGF.beta.-induced anterior subcapsular cataract formation was investigated in a novel mouse MMP-9 knockout model.

IT 198700-79-7 198700-79-7D, analogs or derivs.


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(MMPIs for treatment of TGF.beta.-induced subcapsular cataract formation)

RN 198700-79-7 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-[(1S)-2-oxo-1-[(2,3,4,5,6-pentafluorophenyl)methyl]-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198700-79-7 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-[(1S)-2-oxo-1-[(2,3,4,5,6-pentafluorophenyl)methyl]-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:558817 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:63142

TITLE: Preparation of amino acid urea derivatives as factor Xa inhibitors

INVENTOR(S): Song, Yonghong; Zhu, Bing-Yan; Wang, Shumei; Bhakta, Chhaya; Scarborough, Robert M.

PATENT ASSIGNEE(S): Portola Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 186 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006063113	A2	20060615	WO 2005-US44388	20051207
WO 2006063113	A3	20070510		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, SR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GE, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20060160821	A1	20060720	US 2005-298317	20051207
PRIORITY APPLN. INFO.:			US 2004-634201P	P 20041207

OTHER SOURCE(S): CASREACT 145:63142; MARPAT 145:63142


AB The invention relates to urea derivs. A-Q-D-(CR7R8)m(NR6)nCOCR4R5NR3CONR1R2 [m, n are 0 or 1; D is a direct bond, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heteromonocyclyl, heterobicyclyl; Q is a direct bond, alkylene, CO, CS, O, S, imino, SO2, SO, etc. (at least one of D and Q is not a direct bond); A is amino, amidino, guanidino groups, alkyl, pyridyl oxide, etc.; R1 is H, alkyl, arylalkyl, heteroaryl, alkenyl; R2 is (un)substituted arylalkyl, arylcycloalkyl, heteroaryl, cycloalkyl, etc.; R3-R8 are H, (un)substituted alkyl, alkenyl, cycloalkyl, etc.; or R4 may form a ring with R5 or R6] and their pharmaceutically-acceptable salts and prodrugs which are inhibitors of Factor Xa and are used to prevent or treat a no. of conditions characterized by undesired thrombosis. Thus, N-[[4-(chlorophenyl)amino]carbonyl]glycine [4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl]amide was prepd. by reaction of Boc-protected glycine with 4-aminobenzonitrile, iodomethane, N-methylethylenediamine, and 4-chlorophenyl isocyanate. The product showed IC50 .ltoreq. 100 nM for inhibition of factor Xa.

IT 891789-82-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (prepn. of amino acid urea derivs. as factor Xa inhibitors)

RN 891789-82-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-[4-(hexahydro-1H-azepin-4-yl)-1-piperazinyl]-1-(2-methoxyphenyl)-2-oxoethyl]- (CA INDEX NAME)





IT 855524-53-7P 891789-13-2P 891789-21-2P  
 891789-34-7P 891789-39-2P 891789-48-3P  
 891789-57-4P 891789-58-5P 891789-71-2P  
 891789-72-3P 891789-73-4P 891789-74-5P  
 891789-75-6P 891789-76-7P 891789-77-8P  
 891789-78-9P 891789-79-0P 891789-80-3P  
 891789-81-4P 891789-83-6P 891789-84-7P  
 891789-85-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(prepn. of amino acid urea derivs. as factor Xa inhibitors)

RN 855524-53-7 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 891789-13-2 CAPLUS

CN Urea, N-[1-(2-bromophenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)




RN 891789-21-2 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[1-(2-methylphenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 891789-34-7 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-[1-(2-chlorophenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 891789-39-2 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-[1-(2-methoxyphenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]- (CA INDEX NAME)



RN 891789-48-3 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-[1-(2-iodophenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 891789-57-4 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-[1-(2-fluorophenyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]- (CA INDEX NAME)



RN 891789-58-5 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)



RN 891789-71-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-oxo-2-(2-oxo[1,4'-bipiperidin]-1'-yl)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 891789-72-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-oxo-2-[4-(3-oxo-4-morpholinyl)-1-piperidinyl]-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 891789-73-4 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-oxo-2-[4-(2-oxo-1(2H)-pyridinyl)-1-piperidinyl]-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 891789-74-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[1-(2-fluorophenyl)-2-oxo-2-[4-(3-oxo-4-morpholinyl)-1-piperidinyl]ethyl]- (CA INDEX NAME)




RN 891789-75-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[1-(2-chlorophenyl)-2-oxo-2-[4-(3-oxo-4-morpholinyl)-1-piperidinyl]ethyl]- (CA INDEX NAME)




RN 891789-76-7 CAPLUS

CN Urea, N-[1-(2-bromophenyl)-2-oxo-2-[4-(3-oxo-4-morpholinyl)-1-piperidinyl]ethyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)




RN 891789-77-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[1-(2-methylphenyl)-2-oxo-2-[4-(3-oxo-4-morpholinyl)-1-piperidinyl]ethyl]- (CA INDEX NAME)




RN 891789-78-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[1-(2-methoxyphenyl)-2-oxo-2-[4-(3-oxo-4-morpholinyl)-1-piperidinyl]ethyl]- (CA INDEX NAME)




RN 891789-79-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[1-(2-fluorophenyl)-2-oxo-2-(2-oxo[1,4'-bipiperidin]-1'-yl)ethyl]- (CA INDEX NAME)




RN 891789-80-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[1-(2-methoxyphenyl)-2-oxo-2-(2-oxo[1,4'-bipiperidin]-1'-yl)ethyl]- (CA INDEX NAME)




RN 891789-81-4 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[1-(2-methoxyphenyl)-2-[4-(4-methyl-2-oxo-1-piperazinyl)-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)



RN 891789-83-6 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[2-[4-(hexahydro-1-methyl-1H-azepin-4-yl)-1-piperazinyl]-1-(2-methoxyphenyl)-2-oxoethyl]- (CA INDEX NAME)



RN 891789-84-7 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 891789-85-8 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[hexahydro-4-(1-methyl-4-piperidinyl)-1H-1,4-diazepin-1-yl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L4 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2005:638773 CAPLUS Full-text  
DOCUMENT NUMBER: 143:133401  
TITLE: Preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists  
INVENTOR(S): Degnan, Andrew P.; Chen, Ling; Civiello, Rita; Dubowchik, Gene M.; Han, Xiaojun; Jiang, Xiang Jun J.; Macor, John E.; Tora, George  
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
SOURCE: PCT Int. Appl., 385 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005065779	A1	20050721	WO 2003-US38799	<u>20031205</u>
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2549330	A1	20050721	CA 2003-2549330	20031205
AU 2003297694	A1	20050812	AU 2003-297694	20031205
EP 1689493	A1	20060816	EP 2003-819270	20031205
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003018637	A	20070213	BR 2003-18637	20031205
CN 1917921	A	20070221	CN 2003-80111030	20031205

JP 2007524568	T	20070830	JP 2005-513137	20031205
TW 284534	B	20070801	TW 2004-93137052	20041201
IN 2006DN02822	A	20070803	IN 2006-DN2822	20060518
MX 2006006070	A	20060719	MX 2006-6070	20060529
ZA 2006004503	A	20071128	ZA 2006-4503	20060601
NO 2006002648	A	20060802	NO 2006-2648	20060608
KR 2006125832	A	20061206	KR 2006-713470	20060704
PRIORITY APPLN. INFO.:			EP 2003-819270	T0 20031205
			WO 2003-US38799	W 20031205
OTHER SOURCE(S):	MARPAT 143:133401			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Diazaheterocycles I [m, n = 0-2; V = (un)substituted NH<sub>2</sub>, OH; Q = (un)substituted alkyl, NH<sub>2</sub>, NHCO<sub>2</sub>H, NHCONH<sub>2</sub>; U = CH<sub>2</sub>, NH; D = O, NCN, alkylsulfonylimino; A = C, N, CH; E = (un)substituted heterocyclic; with provisos] were prepd. for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing assocd. with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). E.g., a multi-step synthesis of II which had IC<sub>50</sub> for calcitonin gene related peptide receptor binding of .ltoreq. 10 nM, was given. The pharmaceutical compn. comprising the compd. I is claimed.

IT 635711-71-6P 635711-72-7P 635711-73-8P  
 635711-75-0P 635711-76-1P 635711-77-2P  
 635711-78-3P 635711-79-4P 635711-80-7P  
 635711-82-9P 635711-83-0P 635711-84-1P  
 635711-86-3P 635711-87-4P 635711-88-5P  
 635711-89-6P 635711-90-9P 635711-92-1P  
 635711-93-2P 635711-94-3P 635711-95-4P  
 635711-96-5P 635711-97-6P 635711-98-7P  
 635711-99-8P 635712-00-4P 635712-01-5P  
 635712-02-6P 635712-04-8P 635712-05-9P  
 635712-08-2P 635712-09-3P 635712-10-6P  
 635712-11-7P 635712-12-8P 635712-13-9P  
 635712-14-0P 635712-15-1P 635712-16-2P  
 635712-17-3P 635712-19-5P 635712-20-8P  
 635712-22-0P 635712-23-1P 635712-24-2P  
 635712-25-3P 635712-26-4P 635712-27-5P  
 635712-29-6P 635712-29-7P 635712-30-0P  
 635712-31-1P 635712-32-2P 635712-33-3P  
 635712-34-4P 635712-35-5P 635712-38-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of diazaheterocycles as calcitonin gene related peptide receptor antagonists)

RN 635711-71-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-2-naphthalenyl- (CA INDEX NAME)

Absolute stereochemistry.






RN 635711-72-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-73-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-1-naphthalenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-75-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4,5-trimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-76-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-77-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-78-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-79-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-80-7 CAPLUS

CN Urea, N-[1,1'-biphenyl]-4-yl-N'--[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-82-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-83-0 CAPLUS

CN Urea, N-(3-acetylphenyl)-N'-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-84-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-86-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-87-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-88-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-89-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-90-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 635711-92-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethoxyphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-93-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-difluorophenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-94-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethylphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-95-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,4-dimethylphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-96-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-97-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-98-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dichlorophenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-99-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-(1-methylethyl)phenyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-00-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-difluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-01-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-dichloro-4-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-02-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-04-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[2-chloro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-05-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3,4-trifluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-08-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-09-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-chlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-10-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dichlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 635712-11-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-12-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-13-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-14-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-15-1 CAPLUS

CN Urea, N-[ (1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-16-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-17-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-19-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-20-8 CAPLUS

CN Benzoic acid, 4-[[[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-22-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-difluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-23-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-24-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-25-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-26-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-chloro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-27-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-28-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 635712-29-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-30-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-31-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-32-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromo-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-33-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-fluoro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-34-4 CAPLUS

CN Benzoic acid, 3-[[[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-35-5 CAPLUS

CN Urea, N-[1,1'-biphenyl]-2-yl-N'-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-38-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD  
(5 CITINGS)  
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2005:564638 CAPLUS Full-text  
DOCUMENT NUMBER: 143:97382  
TITLE: Preparation of urea derivatives as activated blood  
coagulation factor X (FXa) inhibitors  
INVENTOR(S): Kubo, Keiji; Imaeda, Yasuhiro  
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan  
SOURCE: PCT Int. Appl., 236 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent \*\*Current app\*\*  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058823	A1	20050630	WO 2004-JP18717	20041215
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CI, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2550012	A1	20050630	CA 2004-2550012	20041215
EP 1695961	A1	20060830	EP 2004-807076	20041215
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
US 20070093501	A1	20070426	US 2006-583046	20060615
PRIORITY APPLN. INFO.:			JP 2003-420031	A 20031217
			WO 2004-JP18717	W 20041215

OTHER SOURCE(S): MARPAT 143:97382  
GI



AB The title compds. I [Cy represents an optionally substituted arom. hydrocarbon group or optionally substituted arom. heterocyclic group; R1 represents hydrogen or an optionally substituted hydrocarbon group; V represents C(O), S(O), or S(O)<sub>2</sub>; W represents N(R<sub>2</sub>), O, or a bond (R<sub>2</sub> represents hydrogen or an optionally substituted hydrocarbon group); X represents optionally substituted alkylene; Y represents C(O), S(O), or S(O)<sub>2</sub>; Z represents a bond, an optionally substituted chain hydrocarbon group, etc. ; ring A represents an optionally substituted nonarom. nitrogenous heterocycle; ring B represents an optionally substituted nitrogenous heterocycle; and the dotted line indicates a single bond or double bond; provided that R1 may be bonded to R2 to form an optionally substituted nonarom. nitrogenous heterocycle and that R2 may be bonded to a substituent of X to form an optionally substituted nonarom. nitrogenous heterocycle] are prepd. Thus, N-(4-chlorophenyl)-N'-(1R)-2,2-dimethyl-1-((3-(3-oxo-1H-imidazo[1,5-a]imidazol-2(3H)-yl)-1-pyrrolidinyl)carbonylpropyl)urea was prepd. in several steps from 1-benzyl-3-pyrrolidinamine and imidazole-2-carbaldehyde. Compds. of this invention in vitro showed IC<sub>50</sub> values of 10 nM to 50 nM against FXa. Formulations are given.

IT

856415-69-5P	856415-70-8P	856415-72-0P
856415-74-2P	856415-75-3P	856415-76-4P
856415-77-5P	856415-78-6P	856415-79-7P
856415-80-0P	856415-81-1P	856415-82-2P
856415-83-3P	856415-85-5P	856415-86-6P
856415-87-7P	856415-88-8P	856415-89-9P
856415-90-2P	856415-91-3P	856415-92-4P
856415-93-5P	856415-94-6P	856415-95-7P
856415-96-8P	856415-97-9P	856415-98-0P
856416-00-7P	856416-01-8P	856416-02-9P
856416-03-0P	856416-04-1P	856416-05-2P
856416-06-3P	856416-07-4P	856416-08-5P
856416-09-6P	856416-10-9P	856416-11-0P
856416-12-1P	856416-13-2P	856416-14-3P
856416-15-4P	856416-16-5P	856416-17-6P
856416-18-7P	856416-19-8P	856416-22-3P
856416-23-4P	856416-24-5P	856416-25-6P
856416-26-7P	856416-27-8P	856416-28-9P
856416-29-0P	856416-30-3P	856416-31-4P
856416-32-5P	856416-33-6P	856416-34-7P
856416-35-8P	856416-36-9P	856416-37-0P
856416-38-1P	856416-39-2P	856416-40-5P
856416-41-6P	856416-42-7P	856416-43-8P
856416-44-9P	856416-45-0P	856416-46-1P
856416-47-2P	856416-48-3P	856416-51-8P
856416-52-9P	856416-53-0P	856416-54-1P
856416-56-3P	856416-57-4P	856416-58-5P
856416-59-6P	856416-60-9P	856416-61-0P
856416-62-1P	856416-63-2P	856416-68-7P
856416-69-8P	856416-70-1P	856416-71-2P
856416-72-3P	856416-73-4P	856416-74-5P
856416-75-6P	856416-82-5P	856416-83-6P


856416-84-7P	856416-85-8P	856416-86-9P
856416-87-0P	856416-88-1P	856416-89-2P
856416-90-5P	856416-91-6P	856416-92-7P
856416-93-8P	856416-94-9P	856416-95-0P
856416-96-1P	856416-97-2P	856416-98-3P
856416-99-4P	856417-00-0P	856417-01-1P
856417-02-2P	856417-07-7P	856417-08-8P
856419-82-4P	856419-83-5P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of urea derivs. as activated blood coagulation factor X inhibitors)


RN 856415-69-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidiny]-2-oxo-1-(phenylmethyl)ethyl]- (CA INDEX NAME)




RN 856415-70-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperaziny]-2-oxo-1-(phenylmethyl)ethyl]- (CA INDEX NAME)




RN 856415-72-0 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperaziny]-3-oxo-2-phenylpropyl]- (CA INDEX NAME)




RN 856415-74-2 CAPLUS  
 CN Urea, N-(4-chlorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidiny]-2-oxoethyl]- (CA INDEX NAME)



RN 856415-75-3 CAPLUS  
 CN Urea, N'-(4-chlorophenyl)-N-methyl-N-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidiny]-2-oxoethyl]- (CA INDEX NAME)




RN 856415-76-4 CAPLUS  
 CN Urea, N-(4-chlorophenyl)-N'-[3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidiny]-3-oxopropyl]- (CA INDEX NAME)



RN 856415-77-5 CAPLUS  
 CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidiny]-2-oxo-1-(phenylmethyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 856415-78-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-79-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyll]-2-oxo-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-80-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1S)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyll]-2-oxo-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-81-1 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-82-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1S)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-83-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-methyl-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-85-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-86-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-87-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1S)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-(phenylmethyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-88-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-3-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]butyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-89-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-90-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-91-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R,2S)-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]butyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856415-92-4 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[(1R,2S)-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856415-93-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[1-cyclopropyl-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 856415-94-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[1-cyclopropyl-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 856415-95-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-ethyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]butyl]- (CA INDEX NAME)



RN 856415-96-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-ethyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]butyl]- (CA INDEX NAME)




RN 856415-97-9 CAPLUS

CN 1-Piperazinepropanoic acid, .alpha.-[[[(4-


chlorophenyl)amino]carbonyl]amino]-4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-.beta.-oxo-, methyl ester, (.alpha.R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 856415-98-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[1-(methoxymethyl)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 856416-00-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[1-cyclopentyl-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxoethyl]- (CA INDEX NAME)



RN 856416-01-8 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[1-(ethoxymethyl)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxoethyl]- (CA INDEX NAME)



RN 856416-02-9 CAPLUS


CN Urea, N'-(4-chlorophenyl)-N-methyl-N-[(1R)-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856416-03-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-hydroxy-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)



RN 856416-04-1 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[2-hydroxy-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]propyl]- (CA INDEX NAME)






RN 856416-05-2 CAPLUS

CN Urea, N-[2-[(aminocarbonyl)oxy]-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]propyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)




RN 856416-06-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-ethyl-2-hydroxy-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]butyl]- (CA INDEX NAME)



RN 856416-07-4 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[2-ethyl-2-hydroxy-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]butyl]- (CA INDEX NAME)



RN 856416-08-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1S)-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]-2-(methylthio)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-09-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[ (1S)-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]-2-(methylsulfinyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-10-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[ (1S)-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]-2-(methylsulfonyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-11-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[ (1S)-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]-2-(methylthio)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-12-1 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[ (1S)-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]-2-(methylsulfinyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-13-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[ (1S)-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]-2-(methylsulfonyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-14-3 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[ (1S)-2-[(2-methoxyethyl)thio]-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856416-15-4 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[1-methyl-3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidiny]-3-oxopropyl]- (CA INDEX NAME)




RN 856416-16-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-methyl-3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidiny]-3-oxopropyl]- (CA INDEX NAME)




RN 856416-17-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidiny]-3-oxo-1-phenylpropyl]- (CA INDEX NAME)




RN 856416-18-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-3-oxo-1-phenylpropyl]- (CA INDEX NAME)




RN 856416-19-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2,2-dimethyl-1-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxoethyl]propyl]- (CA INDEX NAME)




RN 856416-22-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyll]-2-oxo-1-phenylethyl]- (CA INDEX NAME)




RN 856416-23-4 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyll]-2-oxo-1-(2-thienyl)ethyl]- (CA INDEX NAME)



RN 856416-24-5 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxo-1-(2-thienyl)ethyl]- (CA INDEX NAME)



RN 856416-25-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[(4-cyanophenyl)methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-26-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-27-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[(4-hydroxyphenyl)methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-28-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-(3-pyridinylmethyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-29-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxo-1-(4-pyridinylmethyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-30-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyll]-2-oxo-1-(2-thienylmethyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856416-31-4 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyll]carbonyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 856416-32-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidiny]carbonyl]butyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-33-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidiny]carbonyl]pentyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-34-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-cyclohexyl-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidiny]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-35-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-cyclohexyl-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-36-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidiny]carbonyl]-3-(methylthio)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-37-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]-3-(methylthio)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-38-1 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[ (1R)-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidiny]carbonyl]-3-(methylsulfinyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-39-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[ (1R)-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidiny]carbonyl]-3-(methylsulfonyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-40-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[ (1R)-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidiny]carbonyl]-2-(phenylmethoxy)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-41-6 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[ (1R)-2-hydroxy-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856416-42-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethyl]- (CA INDEX NAME)




RN 856416-43-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[1-(1-hydroxycyclohexyl)-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)




RN 856416-44-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-methoxy-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)




RN 856416-45-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-methoxy-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]propyl]- (CA INDEX NAME)




RN 856416-46-1 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-ethoxy-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)




RN 856416-47-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-ethoxy-2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]propyl]- (CA INDEX NAME)




RN 856416-48-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[3-methoxy-2,2-dimethyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]propyl]- (CA INDEX NAME)




RN 856416-51-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]pentyl]- (CA INDEX NAME)




RN 856416-52-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2-methyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)




RN 856416-53-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[2,2-dimethyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl]carbonyl]propyl]- (CA INDEX NAME)



RN 856416-54-1 CAPLUS


CN Urea, N-(4-chlorophenyl)-N-methyl-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidiny]-2-oxo-1-phenylethyl]- (CA INDEX NAME)



RN 856416-56-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[[3-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-pyrrolidinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-57-4 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[[3-(3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-pyrrolidinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-58-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-(5,7-dimethyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidiny]carbonyl]-2,2-dimethylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-59-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[[4-(7-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidiny]carbonyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856416-60-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-(5,7-dimethyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperaziny]carbonyl]-2,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 856416-61-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-(7,8-dihydro-1-methyl-5-oxoimidazo[1,5-c]pyrimidin-6(5H)-yl)-1-piperidinyl]carbonyl]-2,2-dimethylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-62-1 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-(7,8-dihydro-3-methyl-5-oxoimidazo[1,5-c]pyrimidin-6(5H)-yl)-1-piperidinyl]carbonyl]-2,2-dimethylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-63-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-(7,8-dihydro-5-oxoimidazo[1,5-c]pyrimidin-6(5H)-yl)-1-piperidinyl]carbonyl]-2,2-dimethylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-68-7 CAPLUS

~~CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]propyl]- (CA INDEX NAME)~~


Absolute stereochemistry.



RN 856416-69-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[(2-oxo[1,4'-bipiperidin]-1'-yl)carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-70-1 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-71-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[[4-(2-oxo-1-imidazolidinyl)-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-72-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[[4-(3-methyl-2-oxo-1-imidazolidinyl)-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-73-4 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[[4-(4-methyl-2-oxo-1-piperazinyl)-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-74-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[[4-(3-oxo-4-morpholinyl)-1-piperidinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-75-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-(1,1-dioxido-2-isothiazolidinyl)-1-piperidinyl]carbonyl]-2,2-dimethylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-82-5 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-(2-methylimidazo[1,2-a]pyridin-5-yl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-83-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[[4-(2-methylimidazo[1,2-a]pyridin-5-yl)-1-piperazinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856416-84-7 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2,2-dimethyl-1-[[4-(2-methyl-4-pyridinyl)-1-piperazinyl]carbonyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856416-85-8 CAPLUS

CN Urea, N-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]-N'-phenyl- (CA INDEX NAME)




RN 856416-86-9 CAPLUS

CN Urea, N-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]-N'-(4-methylphenyl)- (CA INDEX NAME)




RN 856416-87-0 CAPLUS

CN Urea, N-(4-methoxyphenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)




RN 856416-88-1 CAPLUS

CN Urea, N-(4-fluorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)




RN 856416-89-2 CAPLUS

CN Urea, N-(4-bromophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)




RN 856416-90-5 CAPLUS

CN Urea, N-(4-cyanophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)




RN 856416-91-6 CAPLUS

CN Urea, N-(3-chlorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)




RN 856416-92-7 CAPLUS

CN Urea, N-(2-chlorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)




RN 856416-93-8 CAPLUS

CN Urea, N-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 856416-94-9 CAPLUS

CN Urea, N-(4-chloro-2-methylphenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)



RN 856416-95-0 CAPLUS

CN Urea, N-(2,4-dichlorophenyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)




RN 856416-96-1 CAPLUS

CN Urea, N-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]-N'-[4-(chlorophenyl)]- (CA INDEX NAME)




piperidinyl]-2-oxo-1-phenylethyl]-N'-[4-(methylthio)phenyl]- (CA INDEX NAME)




RN 856416-97-2 CAPLUS

CN Urea, N-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]-N'-[4-(methylsulfinyl)phenyl]- (CA INDEX NAME)




RN 856416-98-3 CAPLUS

CN Urea, N-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]-N'-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 856416-99-4 CAPLUS

CN Benzoic acid, 4-[[[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 856417-00-0 CAPLUS

CN Urea, N-(5-chloro-2-pyridinyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)




RN 856417-01-1 CAPLUS

CN Urea, N-(6-chloro-3-pyridinyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)



RN 856417-02-2 CAPLUS


CN Urea, N-(5-chloro-2-pyrimidinyl)-N'-[2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)



RN 856417-07-7 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-[(2Z)-2,3-dihydro-3-methyl-2-(methylimino)-5-thiazolyl]-1-piperidinyl]carbonyl]-2,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 856417-08-8 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-[(2Z)-2,3-dihydro-3-methyl-2-(methylimino)-5-thiazolyl]-1-piperidinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 856419-82-4 CAPLUS  
CN Urea, N-[(1R)-2,2-dimethyl-1-[[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl]-1-piperazinyl]carbonyl]propyl]-N'-(4-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 856419-83-5 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-[5-(hydroxymethyl)-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl]-1-piperidinyl]carbonyl]-2,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
(2 CITINGS)

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:540568 CAPLUS Full-text

DOCUMENT NUMBER: 143:78086

TITLE: Preparation of urea/carbamate derivatives as  
inhibitors of coagulation factor Xa for treatment of  
thromboembolic disorders

INVENTOR(S): Cezanne, Bertram; Dorsch, Dieter; Mederski, Werner;  
Tsaklakidis, Christos; Gleitz, Johannes

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005056528	A1	20050623	WO 2004-EP13202	20041119
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10358539	A1	20050707	DE 2003-10358539	20031215
AU 2004296956	A1	20050623	AU 2004-296956	20041119
CA 2549548	A1	20050623	CA 2004-2549548	20041119
EP 1694643	A1	20060830	EP 2004-820053	20041119
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
CN 1890216	A	20070103	CN 2004-80036500	20041119
BR 2004017153	A	20070306	BR 2004-17153	20041119
JP 2007513987	T	20070531	JP 2006-544246	20041119
IN 2006KN01578	A	20070504	IN 2006-KN1578	20060608
MX 2006006593	A	20060731	MX 2006-6593	20060609

KR 2006123305	A	20061201	KR 2006-711538	20060612
US 20070123509	A1	20070531	US 2006-582850	20060614
ZA 2006005839	A	20071031	ZA 2006-5839	20060714
PRIORITY APPLN. INFO.:			DE 2003-10358539	<del>A</del> 20031215
			WO 2004-EP13202	W 20041119
OTHER SOURCE(S):			CASREACT 143:78086; MARPAT 143:78086	
GI				



AB Title compds. I [D = halo, alkoxy, etc.; X = amino, O; Y = O, S, amino, etc.; R1 = H, aryl, heteroaryl, etc.; E = CH, N; Z, Z' = acyl, etc.; Q = O, amino, acyl, etc.; R4-4' = A, OH, alkoxy; T = (hetero)cyclyl, etc.] are prepd. For instance, (R)-N-(4-chlorophenyl)-N'-[2-[4-(4-fluorophenyl)piperazin-1-yl]-2-oxo-1-phenylethyl]urea (II) is prepd. in 3 steps from 1-methyl-4,4'-bipiperidinyl, (R)-N-(tert-butoxycarbonyl)phenylglycine and 4-chlorophenylisocyanate. II has IC50 = 6 x 10<sup>-9</sup> M for Factor Xa. I are inhibitors of coagulation factor Xa and can be used for the prophylaxis and/or the treatment of thromboembolic diseases and for treating tumors.

IT 855524-53-7P, (R)-N-(4-Chlorophenyl)-N'-[2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-phenylethyl]urea 855524-59-3P, (R)-N-(4-Chlorophenyl)-N'-[2-oxo-1-phenyl-2-(4-(pyridin-4-yl)piperazin-1-yl)ethyl]urea 855524-60-6P 855524-62-8P 855524-64-0P 855524-68-4P 855524-70-8P 855524-72-0P 855524-73-1P, (R)-N-(4-Chlorophenyl)-N'-[1-((4-(pyridin-4-yl)piperazin-1-yl)carbonyl)butyl]urea 855524-78-6P, (R)-N-(4-Chlorophenyl)-N'-[2-oxo-1-phenyl-2-(4-(pyridin-2-yl)piperazin-1-yl)ethyl]urea 855524-81-1P, (R)-N-(4-Chlorophenyl)-N'-[2-[4-(4,6-dimethylpyrimidin-2-yl)piperazin-1-yl]-2-oxo-1-phenylethyl]urea 855524-83-3P 855524-84-4P 855524-88-8P 855524-89-9P, (R)-N-(2-([4,4']Bipiperidinyl-1-yl)-2-oxo-1-phenylethyl)-N'-(4-chlorophenyl)urea hydrochloride 855524-90-2P, (R)-N-[2-([4,4']Bipiperidinyl-1-yl)-1-(4-hydroxyphenyl)-2-oxoethyl]-N'-(4-chlorophenyl)urea hydrochloride 855524-91-3P, (R)-N-(2-([4,4']Bipiperidinyl-1-yl)-2-oxo-1-(thiophen-2-yl)ethyl)-N'-(4-chlorophenyl)urea hydrochloride 855524-93-5P, (R)-N-(4-Chlorophenyl)-N'-[1-(4-hydroxyphenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl]urea trifluoroacetate 855524-95-7P, (R)-N-(4-Chlorophenyl)-N'-[2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-(thiophen-2-yl)ethyl]urea trifluoroacetate 855524-97-9P, (R)-N-(4-Chlorophenyl)-N'-[1-(4-hydroxyphenyl)-2-(4-(morpholin-4-yl)piperidin-1-yl)-2-oxoethyl]urea trifluoroacetate 855524-98-0P, N-[2-([1,4']Bipiperidinyl-1'-yl)-1-(4-hydroxyphenyl)-2-oxoethyl]-N'-(4-chlorophenyl)urea 855525-00-7P, (R)-N-(4-Chlorophenyl)-N'-[2-(4-(morpholin-4-yl)piperidin-1-yl)-2-oxo-1-phenylethyl]urea trifluoroacetate 855525-02-9P, (R)-N-(2-([1,4']Bipiperidinyl-1'-yl)-2-oxo-1-phenylethyl)-N'-(4-chlorophenyl)urea trifluoroacetate 855525-08-5P 855525-10-9P 855525-12-1P, (R)-N-(4-Chlorophenyl)-N'-[2-(4-(morpholin-4-yl)piperidin-1-yl)-2-oxo-1-

(thiophen-2-yl)ethyl]urea trifluoroacetate 855525-14-3P,  
 (R)-N-(2-([1,4']Bipiperidinyl-1'-yl)-2-oxo-1-(thiophen-2-yl)ethyl)-N'-(4-chlorophenyl)urea trifluoroacetate 855525-18-7P  
 855525-19-8P, (R)-N-(4-Chlorophenyl)-N'-[2-(1'-methyl-[4,4']bipiperidinyl-1-yl)-2-oxo-1-(2-chlorophenyl)ethyl]urea  
 855525-20-1P, (R)-N-(4-Chlorophenyl)-N'-[2-([4,4']bipiperidinyl-1-yl)-2-oxo-1-(2-chlorophenyl)ethyl]urea 855525-21-2P  
 855525-22-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of urea/carbamate derivs. as inhibitors of coagulation factor Xa for treatment of thromboembolic disorders)

RN 855524-53-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxo-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 855524-59-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 855524-60-6 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-oxo-1-phenyl-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 855524-59-3

CMF C24 H24 Cl N5 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 855524-62-8 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-(1-methyl-4-piperidiny)]-1-piperazinyl]-2-oxo-1-phenylethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 855524-61-7

CMF C25 H32 Cl N5 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 855524-64-0 CAPLUS  
 CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-(4-ethyl-1-piperazinyl)-1-piperidinyl]-2-oxo-1-phenylethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 855524-63-9  
 CMF C26 H34 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 855524-68-4 CAPLUS  
 CN Urea, N-(4-chlorophenyl)-N'-[(1R,2R)-2-methoxy-1-[[4-(4-pyridinyl)-1-piperazinyl]carbonyl]propyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 855524-67-3  
 CMF C21 H26 Cl N5 O3

Absolute stereochemistry.






CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 855524-70-8 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[(1R,2R)-2-methoxy-1-[[4-(1-methyl-4-piperidiny)-1-piperazinyl]carbonyl]propyl]-, 2,2,2-trifluoroacetate (1:2)  
(CA INDEX NAME)

CM 1

CRN 855524-69-5

CMF C22 H34 Cl N5 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 855524-72-0 CAPLUS  
 CN Urea, N-(4-chlorophenyl)-N'-[(1R,2R)-2-methoxy-1-[(1'-methyl[4,4'-bipiperidin]-1-yl)carbonyl]propyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 855524-71-9  
 CMF C23 H35 Cl N4 O3

Absolute stereochemistry.




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2



RN 855524-73-1 CAPLUS  
 CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-[[4-(4-pyridinyl)-1-piperazinyl]carbonyl]butyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 855524-78-6 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-oxo-1-phenyl-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 855524-81-1 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-(4,6-dimethyl-2-pyrimidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 855524-83-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1S,2S)-2-hydroxy-1-[[4-(4-pyridinyl)-1-piperazinyl]carbonyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 855524-84-4 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1S,2S)-2-hydroxy-1-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 855524-88-8 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[(1R,2R)-1-[[4-(4-ethyl-1-piperazinyl)-1-piperidinyl]carbonyl]-2-methoxypropyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 855524-87-7

CMF C23 H36 Cl N5 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 855524-89-9 CAPLUS

CN Urea, N-[(1R)-2-[4,4'-bipiperidin]-1-yl-2-oxo-1-phenylethyl]-N'-(4-chlorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 855524-90-2 CAPLUS

CN Urea, N-[(1R)-2-[4,4'-bipiperidin]-1-yl-1-(4-hydroxyphenyl)-2-oxoethyl]-N'-(4-chlorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 855524-91-3 CAPLUS

CN Urea, N-[(1R)-2-[4,4'-bipiperidin]-1-yl-2-oxo-1-(2-thienyl)ethyl]-N'-(4-chlorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 855524-93-5 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-(4-hydroxyphenyl)-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855524-92-4

CMF C26 H33 Cl N4 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 855524-95-7 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxo-1-(2-thienyl)ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855524-94-6

CMF C24 H31 Cl N4 O2 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 855524-97-9 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-(4-hydroxyphenyl)-2-[4-(4-morpholinyl)-1-piperidinyl]-2-oxoethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855524-96-8

CMF C24 H29 Cl N4 O4


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 855524-98-0 CAPLUS

CN Urea, N-[2-[1,4'-bipiperidin]-1'-yl-1-(4-hydroxyphenyl)-2-oxoethyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)



RN 855525-00-7 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-(4-morpholinyl)-1-piperidinyl]-2-oxo-1-phenylethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855524-99-1

CMF C24 H29 Cl N4 O3

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2





RN 855525-02-9 CAPLUS


CN Urea, N-[(1R)-2-[1,4'-bipiperidin]-1'-yl-2-oxo-1-phenylethyl]-N'-(4-chlorophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855525-01-8

CMF C25 H31 Cl N4 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 855525-08-5 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-(4-hydroxyphenyl)-2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855525-07-4

CMF C25 H32 Cl N5 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 855525-10-9 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxo-1-phenylethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 855525-09-6

CMF C25 H32 Cl N5 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 855525-12-1 CAPLUS  
 CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-(4-morpholinyl)-1-piperidinyl]-2-oxo-1-(2-thienyl)ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 855525-11-0  
 CMF C22 H27 Cl N4 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 855525-14-3 CAPLUS  
 CN Urea, N-[(1R)-2-[1,4'-bipiperidin]-1'-yl-2-oxo-1-(2-thienyl)ethyl]-N'-(4-chlorophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855525-13-2  
 CMF C23 H29 Cl N4 O2 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 855525-18-7 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxo-1-(2-thienyl)ethyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 855525-17-6

CMF C23 H30 Cl N5 O2 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 855525-19-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-(2-chlorophenyl)-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 855525-20-1 CAPLUS

CN Urea, N-[(1R)-2-[4,4'-bipiperidin]-1-yl]-1-(2-chlorophenyl)-2-oxoethyl)-N'-(4-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 855525-21-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-1-(2-chlorophenyl)-2-(1'-methyl-2'-oxo[4,4'-bipiperidin]-1-yl)-2-oxoethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 855525-22-3 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[(1R)-2-(1'-methyl-2'-oxo[4,4'-bipiperidin]-1-yl)-2-oxo-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2004:857166 CAPLUS Full-text  
 DOCUMENT NUMBER: 141:332218  
 TITLE: Preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists  
 INVENTOR(S): Chaturvedula, Prasad V.; Chen, Ling; Civiello, Rita; Conway, Charles Mark; Degnan, Andrew P.; Dubowchik, Gene M.; Han, Xiaojun; Jiang, Xiang Jun; Karageorge, George N.; Luo, Guanglin; Macor, John E.; Poindexter, Graham; Tora, George; Vig, Shikha  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: U.S. Pat. Appl. Publ., 203 pp., Cont.-in-part of U.S. Ser. No. 445,523.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040204397	A1	20041014	US 2003-729155	<u>20031205</u>
US 7220862	B2	20070522		
US 20040063735	A1	20040401	US 2003-445523	20030527
ZA 2004009654	A	20060726	ZA 2004-9654	20041129
US 20070148093	A1	20070628	US 2006-641974	20061219

US 20070149502	A1	20070628	US 2007-620253	20070105
US 20070149503	A1	20070628	US 2007-620308	20070105
US 20070232600	A1	20071004	US 2007-620291	20070105
US 7314883	B2	20080101		

PRIORITY APPLN. INFO.:

US 2002-386138P	P	20020605
US 2002-388617P	P	20020613
US 2002-389870P	P	20020619
US 2002-393200P	P	20020701
US 2002-413534P	P	20020925
US 2003-445523	A2	20030527
US 2003-729155	A3	20031205

OTHER SOURCE(S): MARPAT 141:332218  
GI



AB Diazaheterocycles I [m, n = 0-2; V = (un)substituted NH<sub>2</sub>, OH; Q = (un)substituted alkyl, NH<sub>2</sub>, NHCO<sub>2</sub>H, NHCONH<sub>2</sub>; U = CH<sub>2</sub>, NH; D = O, NCN, alkylsulfonylimino; A = C, N, CH; E = (un)substituted heterocyclic; with provisos] were prepd. for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing assocd. with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Thus, the indazole II was prepd. from 1H-indazole-5-carboxaldehyde and had IC<sub>50</sub> for calcitonin gene related peptide receptor binding of .ltoreq. 10 nM. The pharmaceutical compn. comprising the compd. I is claimed.

IT	635711-71-6P	635711-72-7P	635711-73-8P
	635711-75-0P	635711-76-1P	635711-77-2P
	635711-78-3P	635711-79-4P	635711-80-7P
	635711-82-9P	635711-83-0P	635711-84-1P
	635711-86-3P	635711-87-4P	635711-88-5P
	635711-89-6P	635711-90-9P	635711-92-1P
	635711-93-2P	635711-94-3P	635711-95-4P
	635711-96-5P	635711-97-6P	635711-98-7P
	635711-99-8P	635712-00-4P	635712-01-5P
	635712-02-6P	635712-04-8P	635712-05-9P
	635712-08-2P	635712-09-3P	635712-10-6P
	635712-11-7P	635712-12-8P	635712-13-9P
	635712-14-0P	635712-15-1P	635712-16-2P

635712-17-3P    635712-19-5P    635712-20-8P  
 635712-22-0P    635712-23-1P    635712-24-2P  
 635712-25-3P    635712-26-4P    635712-27-5P  
 635712-28-6P    635712-29-7P    635712-30-0P  
 635712-31-1P    635712-32-2P    635712-33-3P  
 635712-34-4P    635712-35-5P    635712-38-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(prepn. of diazaheterocycles as calcitonin gene related peptide  
 receptor antagonists)

RN 635711-71-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-  
 3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-2-naphthalenyl- (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 635711-72-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-  
 3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-phenoxyphenyl)- (CA  
 INDEX NAME)


Absolute stereochemistry.






RN 635711-73-8 CAPLUS  
 CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-1-naphthalenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-75-0 CAPLUS  
 CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4,5-trimethylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 635711-76-1 CAPLUS  
 CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-77-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-78-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-79-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-80-7 CAPLUS

CN Urea, N-[1,1'-biphenyl]-4-yl-N'--[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-82-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-83-0 CAPLUS

CN Urea, N-(3-acetylphenyl)-N'-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-84-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-86-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-87-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-88-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-89-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-90-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-92-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethoxyphenyl)-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 635711-93-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-difluorophenyl)-  
(CA INDEX NAME)

Absolute stereochemistry.






RN 635711-94-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethylphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-95-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,4-dimethylphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-96-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-97-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-98-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dichlorophenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-99-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-(1-methylethyl)phenyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-00-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-difluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-01-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-dichloro-4-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-02-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-04-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-chloro-5-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-05-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3,4-trifluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-08-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-09-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-10-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-11-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-12-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-ethoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 635712-13-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-14-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-15-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-16-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-17-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-19-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-20-8 CAPLUS

CN Benzoic acid, 4-[[[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-22-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-difluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-23-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-24-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-25-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-26-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-chloro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-27-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-28-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-29-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-2-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-30-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-2-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 635712-31-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-32-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromo-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-33-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-fluoro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-34-4 CAPLUS

CN Benzoic acid, 3-[[[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-35-5 CAPLUS

CN Urea, N-[1,1'-biphenyl]-2-yl-N'-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-38-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD  
(9 CITINGS)  
REFERENCE COUNT: 119 THERE ARE 119 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L4 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:991516 CAPLUS Full-text

DOCUMENT NUMBER: 140:42208

TITLE: Preparation of diazaheterocycles as calcitonin gene  
related peptide receptor antagonists

INVENTOR(S): Chaturvedula, Prasad V.; Chen, Ling; Civiello, Rita;  
Conway, Charles Mark; Degnan, Andrew P.; Dubowchik,  
Gene M.; Han, Xiaojun; Karageorge, George N.; Luo,  
Guanglin; Macor, John E.; Poindexter, Graham; Vig,  
Shikha

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 309 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104236	A1	20031218	WO 2003-US16576	20030527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2487976 A1 20031218 CA 2003-2487976 20030527 AU 2003237255 A1 20031222 AU 2003-237255 20030527 BR 2003011812 A 20050329 BR 2003-11812 20030527 EP 1539766 A1 20050615 EP 2003-736721 20030527 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1671711	A	20050921	CN 2003-818475	20030527
JP 2005538959	T	20051222	JP 2004-511306	20030527
NZ 537315	A	20060428	NZ 2003-537315	20030527
RU 2341526	C2	20081220	RU 2004-139061	20030527
NO 2004005219	A	20050228	NO 2004-5219	20041129
ZA 2004009654	A	20060726	ZA 2004-9654	20041129
MX 2004011960	A	20050331	MX 2004-11960	20041130
IN 2004DN03814	A	20070427	IN 2004-DN3814	20041201
PRIORITY APPLN. INFO.:			US 2002-386138P	P 20020605
			US 2002-388617P	P 20020613
			US 2002-389870P	P 20020619
			US 2002-393200P	P 20020701
			US 2002-413534P	P 20020925
			WO 2003-US16576	W 20030527

OTHER SOURCE(S): MARPAT 140:42208  
GI



AB Diazaheterocycles I [m, n = 0-2; m .noteq. n = 2; V = (un)substituted NH<sub>2</sub>, OH; Q = (un)substituted alkyl, NH<sub>2</sub>, NHCO<sub>2</sub>H, NHCONH<sub>2</sub>; U = CH<sub>2</sub>, NH; D = O, NCN, alkylsulfonylimino; A = C, N, CH; E = (un)substituted heterocyclic] were prepd. for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing assocd. with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Thus, the indazole II was prepd. from 1H-indazole-5-carboxaldehyde and had IC<sub>50</sub> for calcitonin gene related peptide receptor binding of .ltoreq. 10 nM.

IT 635711-71-6P 635711-72-7P 635711-73-8P  
635711-75-0P 635711-76-1P 635711-77-2P  
635711-78-3P 635711-79-4P 635711-80-7P  
635711-82-9P 635711-83-0P 635711-84-1P  
635711-86-3P 635711-87-4P 635711-88-5P  
635711-89-6P 635711-90-9P 635711-92-1P  
635711-93-2P 635711-94-3P 635711-95-4P  
635711-96-5P 635711-97-6P 635711-98-7P  
635711-99-3P 635712-00-4P 635712-01-5P  
635712-02-6P 635712-04-8P 635712-05-9P  
635712-08-2P 635712-09-3P 635712-10-6P  
635712-11-7P 635712-12-8P 635712-13-9P

635712-14-0P	635712-15-1P	635712-16-2P
635712-17-3P	635712-19-5P	635712-20-8P
635712-22-0P	635712-23-1P	635712-24-2P
635712-25-3P	635712-26-4P	635712-27-5P
635712-28-6P	635712-29-7P	635712-30-0P
635712-31-1P	635712-32-2P	635712-33-3P
635712-34-4P	635712-35-5P	635712-38-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(prepn. of diazaheterocycles as calcitonin gene related peptide  
receptor antagonists)

RN 635711-71-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-  
3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-2-naphthalenyl- (CA  
INDEX NAME)


Absolute stereochemistry.



RN 635711-72-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-  
3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-phenoxyphenyl)- (CA  
INDEX NAME)


Absolute stereochemistry.



RN 635711-73-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-1-naphthalenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-75-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4,5-trimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-76-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-77-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-78-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-ethylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 635711-79-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-80-7 CAPLUS

CN Urea, N-[1,1'-biphenyl]-4-yl-N'--[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-82-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-83-0 CAPLUS

CN Urea, N-(3-acetylphenyl)-N'-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-84-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dichlorophenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-86-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methoxyphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-87-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-88-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-89-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-chloro-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-90-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-92-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethoxyphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-93-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-difluorophenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-94-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethylphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-95-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,4-dimethylphenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-96-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dimethylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-97-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 635711-98-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dichlorophenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635711-99-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-(1-methylethyl)phenyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-00-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-difluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-01-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-dichloro-4-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-02-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-04-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-chloro-5-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-05-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3,4-trifluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-08-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-09-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-10-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-11-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-12-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-13-9 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-14-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-15-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-16-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromophenyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 635712-17-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-19-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-20-8 CAPLUS

CN Benzoic acid, 4-[[[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-22-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-difluorophenyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 635712-23-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-24-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-25-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-26-4 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[4-chloro-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-27-5 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-28-6 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-29-7 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-30-0 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-31-1 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-32-2 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromo-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-33-3 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-fluoro-2-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-34-4 CAPLUS

CN Benzoic acid, 3-[[[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.






RN 635712-35-5 CAPLUS

CN Urea, N-[1,1'-biphenyl]-2-yl-N'-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-38-8 CAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)  
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:76556 CAPLUS Full-text  
 DOCUMENT NUMBER: 138:131125  
 TITLE: Fat accumulation-modulating compounds  
 INVENTOR(S): Stevenson, Michael John; Leighton, Harry Jefferson  
 PATENT ASSIGNEE(S): Adipogenix, Inc., USA  
 SOURCE: PCT Int. Appl., 96 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003007888	A2	20030130	WO 2002-US23295	20020722
WO 2003007888	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CS, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002322585	A1	20030303	AU 2002-322585	20020722
US 20030144350	A1	20030731	US 2002-201588	20020722
PRIORITY APPLN. INFO.:			US 2001-306837P	P 20010720
			WO 2002-US23295	W 20020722

OTHER SOURCE(S): MARPAT 138:131125  
 GI




AB The present invention pertains to compds. effective at modulating fatty acid or triglyceride ("fat") accumulation by cells, such compds. having therapeutic potential as regulators of body mass and for the treatment of overweight individuals, obesity, and metabolic disorders. An example compd. is I and protocol for high-throughput screening of compd. efficacy on human preadipocytes is given. Therapeutic methods and pharmaceutical compns. featuring these compds. are also provided.

IT 491868-44-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(fat accumulation-modulating compds.)

RN 491868-44-1 CAPLUS

CN Urea, N-[3-[4-(1H-benzimidazol-2-yl)-1-piperidinyl]-3-oxopropyl]-N'-[3,5-bis(trifluoromethyl)phenyl]-N-cyclohexyl- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD  
(8 CITINGS)  
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:507689 CAPLUS Full-text

DOCUMENT NUMBER: 135:92860

TITLE: Preparation of piperidine-substituted amino-acids for  
use in treatment of CGRP-mediated disorders

INVENTOR(S): Rudolf, Klaus; Eberlein, Wolfgang; Dreyer, Alexander;  
Muller, Stephan Georg; Doods, Henri; Bauer, Eckhart

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: PCT Int. Appl., 153 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049676	A1	20010712	WO 2000-EP13236	20001222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19963868	A1	20010712	DE 1999-19963868	19991230
CA 2395541	A1	20010712	CA 2000-2395541	20001222
CA 2395541	C	20080923		
BR 2000017063	A	20021022	BR 2000-17063	20001222
EP 1252153	A1	20021030	EP 2000-991806	20001222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003000002	A2	20030528	HU 2003-2	20001222
HU 2003000002	A3	20060130		
JP 2003519222	T	20030617	JP 2001-550216	20001222
EE 200200369	A	20031015	EE 2002-369	20001222
CN 1203069	C	20050525	CN 2000-818106	20001222
AU 783275	B2	20051006	AU 2001-35379	20001222
NZ 519939	A	20060831	NZ 2000-519939	20001222
IL 150377	A	20070617	IL 2000-150377	20001222
TW 255267	B	20060521	TW 2000-89128135	20001228
IN 2002MN00796	A	20050304	IN 2002-MN796	20020614
BG 106848	A	20021229	BG 2002-106848	20020620
ZA 2002005181	A	20030930	ZA 2002-5181	20020627
NO 2002003161	A	20020628	NO 2002-3161	20020628
NO 323700	B1	20070625		
MX 2002006509	A	20021129	MX 2002-6509	20020628
US 20030212057	A1	20031113	US 2002-169009	20021107
US 6949541	B2	20050927		
HK 1054026	A1	20050916	HK 2003-106237	20030901
IN 2007MN00174	A	20070817	IN 2007-MN174	20070202
PRIORITY APPLN. INFO.:			DE 1999-19963868	A 19991230
			WO 2000-EP13236	W 20001222
			IN 2002-MN796	A3 20020614

OTHER SOURCE(S) : MARPAT 135:92860  
GI



AB The invention relates to piperidine-substituted .alpha.- or .beta.-amino acids [(I); R = (un)satd. (un)substituted heterocycle; R1 = Ph, naphthyl, (un)substituted heterocycle; R2 = H, alkyl; A, A1 = H; when one of A or A1 = H, the other = NH2, 1,4'-bipiperidyl, alkylamino, N(R3)(Z-R4)(forming

(substituted) .alpha.- or .beta.-amino acid); R3 = H, alkyl; Z = C(O), SO2; R4 = alkoxy, amino, (di)alkylamino, substituted heterocycle] their tautomers, diastereomers, enantiomers, mixts., and to their salts, in particular, their physiol. compatible salts with inorg. or org. acids or bases, which comprise valuable pharmacol. properties, in particular, CGRP-antagonistic properties. The invention also relates to medicaments contg. these compds., to their use and to methods for the prodn. thereof; formulations were given. Prepn. of fragments CO2HC(R2)AC(O)R1, and A or A1 substituents were given. Thus (R,S)-4-(4-amino-3,5-dibromophenyl)-2- [(1,1-dimethylethoxy carbonyl)methylamino]-4-oxo-butanoic acid was reacted with 3-(piperidinyl)-1,3,4,5-tetrahydro-1,3-benzodiazepin-2(2H)-one to give I (R = 1,3,4,5-tetrahydro-1,3-benzodiazepin-2(2H)-one; R1 = 4-amino-3,5-dibromophenyl; R2 = H; A = (1,1-dimethylethoxy carbonyl)methylamino; A1 = H). In in vitro tests using SK-N-MC cells as tests of human CGRP-receptor binding affinity, I had IC50 .ltoreq.10000 nM, and acted as CGRP antagonists at dosages between 10-11 - 10-5 M.


IT 349535-73-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperidine-substituted amino-acids for use in treatment of CGRP-mediated disorders)

RN 349535-73-5 CAPLUS

CN Urea, N-[3-(4-amino-3,5-dibromophenyl)-3-oxo-1-[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]propyl]-N'-2-pyridinyl- (CA INDEX NAME)




OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (22 CITINGS)  
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1999:761524 CAPLUS Full-text  
DOCUMENT NUMBER: 132:12331  
TITLE: Tricyclic antitumor farnesyl protein transferase inhibitors  
INVENTOR(S): Njoroge, F. George; Doll, Ronald J.; Remiszewski, Stacy W.  
PATENT ASSIGNEE(S): Schering Corporation, USA  
SOURCE: U.S., 55 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5994364	A	19991130	US 1997-927467	19970911
US 6277854	B1	20010821	US 1999-352895	19990713
PRIORITY APPLN. INFO.:			US 1996-25872P	P 19960913
			US 1997-49848P	P 19970617
			US 1997-927467	A3 19970911
OTHER SOURCE(S):		MARPAT 132:12331		
GI				




AB The title compds. I [X = CH, C; one of a, b, c, d = N, NR9 and the others = CR1, CR2 or each of a, b, c, d = CR1 or CR2; R1 = H, R2 = Br, R3, R4 = Br, Cl; R5, R6, R7, R8 = H, CF3, alkyl, aryl, etc.; m = 0-5; n = 0, 1; Y = NR21R22 and R21, R22 = H, alkyl, benzyl, etc.; or NR21R22 = pyrrolidino, piperidino, etc.], antitumor farnesyl protein transferase inhibitors, were prepd. E.g., (+)-N-[2-[4-(3-bromo-8,10-dichloro-6,11-dihydro-5H- benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidinyl]-2-oxoethyl]urea was prepd.

IT 251365-92-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of tricyclic antitumor farnesyl protein transferase inhibitors)

RN 251365-92-1 CAPLUS


CN Urea, N-[4-[4-[(11R)-3-bromo-8,10-dichloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-4-oxobutyl]-N'-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)  
 REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1999:234515 CAPLUS Full-text  
 DOCUMENT NUMBER: 131:31909  
 TITLE: Synthesis of a Series of Stromelysin-Selective Thiadiazole Urea Matrix Metalloproteinase Inhibitors  
 AUTHOR(S): Jacobsen, E. Jon; Mitchell, Mark A.; Hendges, Susan K.; Belonga, Kenneth L.; Skaletzky, Louis L.; Stelzer, Lindsay S.; Lindberg, Thomas. J.; Fritzen, Edward L.; Schostarez, Heinrich J.; O'Sullivan, Theresa J.; Maggiora, Linda L.; Stuchly, Christopher W.; Laborde, Alice L.; Kubicek, Marc F.; Poorman, Roger A.; Beck, Joan M.; Miller, Henry R.; Petzold, Gary L.; Scott, Pam S.; Truesdell, Scott E.; Wallace, Tanya L.; Wilks, John W.; Fisher, Christopher; Goodman, Linda V.; Kaytes, Paul S.; Ledbetter, Stephen R.; Powers, Elaine A.; Vogeli, Gabriel; Mott, John E.; Trepod, Catherine M.; Staples, Douglas J.; Baldwin, Eric T.; Finzel, Barry C.  
 CORPORATE SOURCE: Departments of Structural Analytical and Medicinal Chemistry Protein Science Genomics Discovery Technologies Cell and Molecular Biology and Chemical Process Research Preparations, Pharmacia Upjohn, Kalamazoo, MI, 49007, USA  
 SOURCE: Journal of Medicinal Chemistry (1999), 42(9), 1525-1536  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 131:31909  
 GI



AB The synthesis and enzyme inhibition data for a series of thiadiazole urea matrix metalloproteinase inhibitors are described. A broad screening effort was utilized to identify several thiadiazoles which were weak inhibitors of stromelysin. Optimization of the thiadiazole leads to include an .alpha.-amino acid side chain with variable terminal amide substituents provided a series of ureas which were moderately effective stromelysin inhibitors, with Ki's between 0.3 and 1.0 .mu.M. The most effective analogs utilized an L-phenylalanine as the amino acid component. In particular, unsubstituted I (R1 = Ph, R2 = NHMe) had a Ki of 710 nM, while I (R1 = p-fluorophenyl, R2 = NHMe) displayed increased potency (100 nM). Stromelysin inhibition was further improved using a pentafluorophenylalanine substituent which resulted in I (R1 = C6F5, R2 = NHMe), a 14 nM inhibitor. While gelatinase inhibition was generally poor, the use of 1-(2-pyridyl)piperazine as the amide component usually provided for enhanced activity, with I [R1 = C6F5, R2 = 4-(2-pyridyl)-1-piperazinyl] inhibiting gelatinase with a Ki of 770 nM. The combination of this heterocycle with a p-fluorophenylalanine substituent provided the only analog, I [R1 = p-fluorophenyl, R2 = 4-(2-pyridyl)-1-piperazinyl], with collagenase activity (13 .mu.M). The SAR for analogs described within this series can be rationalized through consideration of the x-ray structure recently attained for I (R1 = C6F5, R2 = NHMe) complexed to stromelysin. Uniquely, this structure showed the inhibitor to be completely oriented on the left side of the enzyme cleft. These results suggest that thiadiazole urea heterocycles which incorporate a substituted phenylalanine can provide selective inhibitors of stromelysin. Careful selection of the amide substituent can also provide for analogs with modest gelatinase inhibition.


IT 198700-71-9P 198700-78-6P 198700-79-7P  
198700-83-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors)

RN 198700-71-9 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-[(1S)-2-oxo-1-(phenylmethyl)-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 198700-78-6 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-[(1S)-2-oxo-1-(phenylmethyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).






RN 198700-79-7 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-[(1S)-2-oxo-1-[(2,3,4,5,6-pentafluorophenyl)methyl]-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198700-83-3 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 38 THERE ARE 38 CAPLUS RECORDS THAT CITE THIS RECORD (38 CITINGS)  
 REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:788775 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 130:38702

TITLE: Preparation of thiadiazole derivatives useful for the treatment of diseases related to connective tissue

degradation  
 INVENTOR(S): Jacobsen, Eric J.; Mitchell, Mark A.; Schostarez,  
 Heinrich J.; Harper, Donald E.  
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA  
 SOURCE: U.S., 29 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5847148	A	19981208	US 1997-835599	19970410
PRIORITY APPLN. INFO.:			US 1997-835599	19970410

OTHER SOURCE(S): MARPAT 130:38702

AB Thiadiazole derivs. RNHC(:X)NHCHR1(CHR3)nCOR2 (R = 4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl; X = O, S; R1, R3 = H, alkyl, aralkyl, cycloalkylalkyl, alkoxyalkyl, etc.; R2 = OH, alkoxy, aryloxy, amino group; n = 0, 1) were prepd. for inhibition of various enzymes from the matrix metalloproteinase family, predominantly stromelysins, and thus are useful for the treatment of matrix metallo endoproteinase diseases. Thus, N-[[4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)amino]carbonyl]-L- phenylalanine Me ester, prepd. by reaction of L-phenylalanine Me ester hydrochloride with phosgene and 5-amino-1,3,4-thiadiazole-2-thiol, showed  $K_i = 0.9 \mu\text{M}$  for inhibition of stromelysin.


IT 198700-71-9P 198700-78-6P 198700-79-7P  
 198700-83-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of thiadiazole amino acid derivs. for treatment of diseases related to connective tissue degrdn.)

RN 198700-71-9 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-[(1S)-2-oxo-1-(phenylmethyl)-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198700-78-6 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-[(1S)-2-oxo-1-(phenylmethyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198700-79-7 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-[(1S)-2-oxo-1-[(2,3,4,5,6-pentafluorophenyl)methyl]-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198700-83-3 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:180865 CAPLUS Full-text


DOCUMENT NUMBER: 128:230252

ORIGINAL REFERENCE NO.: 128:45607a, 45610a


TITLE: Preparation of benzocycloheptapyridines as farnesyl

protein transferase inhibitors  
 INVENTOR(S): Njoroge, F. George; Doll, Ronald J.; Remiszewski, Stacy W.  
 PATENT ASSIGNEE(S): Schering Corp., USA  
 SOURCE: PCT Int. Appl., 90 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9811092	A1	19980319	WO 1997-US15899	19970911
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2266015	A1	19980319	CA 1997-2266015	19970911
CA 2266015	C	20031230		
AU 9748011	A	19980402	AU 1997-48011	19970911
EP 929544	A1	19990721	EP 1997-910710	19970911
EP 929544	B1	20041110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO				
CN 1238770	A	19991215	CN 1997-199602	19970911
HU 2000001109	A2	20010428	HU 2000-1109	19970911
JP 2001521489	T	20011106	JP 1998-513758	19970911
AT 282036	T	20041115	AT 1997-910710	19970911
ES 2229340	T3	20050416	ES 1997-910710	19970911
KR 2000036111	A	20000626	KR 1999-702134	19990312
HK 1018446	A1	20050401	HK 1999-103422	19990807
PRIORITY APPLN. INFO.:			US 1996-712989	A 19960913
			US 1997-877400	A 19970617
			WO 1997-US15899	W 19970911
OTHER SOURCE(S):			MARPAT 128:230252	
GI				



I



II

AB Title compds. [I; 1 of a,b,c,d = N or NR9 and the others = CR1 or CR2; A,B = halo, R10, OR11, H2, H and halo, H and alkyl, etc.; R1-R4 = H, halo, alkoxy, (di)alkylamino, etc.; R3R4 = atoms to complete a ring; R5-R8 = H, (alkoxy)alkyl, alkanoyl, aryl, etc.; R9 = oxido, Me, (CH2)nCO2H; R10 = H,


(ar)alkyl, aryl; R11 = alkyl or aryl; X = N, C, CH; n = 1-3; R = (CH<sub>2</sub>)<sub>v</sub>(CO)<sub>w</sub>Y; Y = NR<sub>21</sub>R<sub>22</sub>, alkoxy, OM; M = alkali metal atom; NR<sub>21</sub>,R<sub>22</sub> = H, (cyclo)alkyl, CH<sub>2</sub>CONH<sub>2</sub>, Ph, CH<sub>2</sub>Ph, Bz, alkylsulfonyl, NHPH, acyl, pyridyl, (dialkyl)carbamoyl, CONHPh; NR<sub>21</sub>R<sub>22</sub> = heterocyclyl] were prepd. Thus, title compd. II (R<sub>14</sub> = H) was N-acylated with EtO<sub>2</sub>CCH<sub>2</sub>CO<sub>2</sub>K to give II (R<sub>14</sub> = COCH<sub>2</sub>CO<sub>2</sub>Et). Data for biol. activity of I were given.

IT 204761-71-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of benzocycloheptapyridines as farnesyl protein transferase inhibitors)

RN 204761-71-7 CAPLUS

CN Urea, N-[4-[4-(3-bromo-8,10-dichloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinyl]-4-oxobutyl]-N'-phenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)  
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:717904 CAPLUS Full-text

DOCUMENT NUMBER: 128:3886

ORIGINAL REFERENCE NO.: 128:843a,846a

TITLE: Preparation of thiadiazolyl(thio)ureas useful as matrix metalloprotease inhibitors

INVENTOR(S): Jacobsen, E. Jon; Mitchell, Mark A.; Schostarez, Heinrich Joseph; Harper, Donald E.

PATENT ASSIGNEE(S): Pharmacia & Upjohn Co., USA; Jacobsen, E. Jon; Mitchell, Mark A.; Schostarez, Heinrich Joseph; Harper, Donald E.

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9740031	A1	19971030	WO 1997-US5428	19970410
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,				

LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,  
PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ,  
VN, YU  
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,  
GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,  
ML, MR, NE, SN, TD, TG  
AU 9726036 A 19971112 AU 1997-26036 19970410  
EP 900211 A1 19990310 EP 1997-917801 19970410  
EP 900211 B1 20030702  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI  
JP 2000509039 T 20000718 JP 1997-538079 19970410  
AT 244229 T 20030715 AT 1997-917801 19970410  
ES 2202602 T3 20040401 ES 1997-917801 19970410  
PRIORITY APPLN. INFO.: US 1996-16003P P 19960423  
WO 1997-US5428 W 19970410  
OTHER SOURCE(S): MARPAT 128:3886  
GI



AB Novel thiadiazole derivs. I [X = O, S; R1 = H, C1-6 alkyl, (CH2)0-4-aryl, (CH2)1-4-cycloalkyl, C1-4 alkyl-OR4, C1-4 alkyl-SR4, (CH2)1-4-heteroaryl, CO2R4, CONR52, (CH2)1-4-OSiR44; R2 = OR5, NR6R7; R3 = H, C1-6 alkyl, (CH2)0-4-aryl, (CH2)0-4-cycloalkyl, C1-4 alkyl-OR4, C1-4 alkyl-SR4, OR4; R4 = H, C1-6 alkyl, (CH2)0-4-aryl; R5 = H, C1-6 alkyl, aryl; R6, R7 = independently H, C1-6 alkyl, C1-6-OR4, (CH2)0-4-aryl, (CH2)1-4-cycloalkyl, (CH2)1-4-heteroaryl, CH2Q, (CH2)1-4-CO2R4, (CH2)1-4CONR52, 5-[[5-(dimethylamino)-1-naphthylsulfonyl]amino]pentyl; NR6R7 = azetidino, pyrrolidino, piperidino, morpholino, 4-thiomorpholino, 4-R8-substituted piperazino; R8 = H, C1-6 alkyl, (CH2)1-4-aryl, CHPh2, (CH2)1-4-heteroaryl; Q = satd., 5- or 6-membered heterocycle contg. 1-2 N, O, or S atoms; n = 0, 1] and II (R9 = CH2Ph, CH2CH2Ph), or pharmaceutically acceptable salts thereof, are presented as inhibitors various enzymes from the matrix metalloproteinase family, predominantly stromelysins. Thus, I and II are useful for the treatment of matrix metalloendoproteinase diseases such as osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as osteoporosis, tumor metastasis (invasion and growth), periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, and other diseases related to connective tissue degrdn. Thus, reaction of L-phenylalanine Me ester isocyanate (prepn. given) with 5-amino-1,3,4-thiadiazole-2-thiol in THF gave 58% Me ester III (R = OMe). Amidation of ester III (R = OMe) with MeNH2 gave amide III (R = NHMe). Ureas II (R = OMe, NHMe) and related compds. were tested for stromelysin inhibition, with III (R = OMe, NHMe) having Ki = 0.9 and 0.27 .mu.M, resp.


II 198700-71-9P 198700-78-6P 198700-79-7P  
198700-83-3P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of thiadiazolyl(thio)ureas useful as matrix metalloprotease  
 inhibitors)

RN 198700-71-9 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-[(1S)-2-oxo-1-(phenylmethyl)-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198700-78-6 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-[(1S)-2-oxo-1-(phenylmethyl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198700-79-7 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-[(1S)-2-oxo-1-[(2,3,4,5,6-pentafluorophenyl)methyl]-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 198700-83-3 CAPLUS

CN Urea, N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-N'-[(1S)-1-[(4-fluorophenyl)methyl]-2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)  
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:217658 CAPLUS Full-text

DOCUMENT NUMBER: 120:217658

ORIGINAL REFERENCE NO.: 120:38657a,38660a

TITLE: Preparation and formulation of 2-aryl-3-(ureidoacetyl)thiazolidine-4-carboxylates and analogs as CCK receptor and gastrin receptor ligands  
INVENTOR(S): Capet, Marc; Cotrel, Claude; Guyon, Claude; Joannic, Michel; Manfre, Franco; Roussel, Gerard; Dubroeuq, Marie Christine; Cheve, Michel; Dutruc-Rosset, Gilles

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer SA, Fr.

SOURCE: PCT Int. Appl., 186 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9301167	A1	19930121	WO 1992-FR626	<u>19920703</u>
W: AU, CA, CS, FI, HU, JP, KR, NO, PL, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
FR 2678938	A1	19930115	FR 1991-8675	19910710
FR 2678938	B1	19931008		
EP 527069	A1	19930210	EP 1992-401904	19920703
R: PT				
AU 9223275	A	19930211	AU 1992-23275	19920703
AU 662345	B2	19950831		
EP 593639	A1	19940427	EP 1992-915456	19920703
EP 593639	B1	19950405		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06509331	T	19941020	JP 1992-502018	19920703
JP 3034043	B2	20000417		
AT 120732	T	19950415	AT 1992-915456	19920703
ES 2071510	T3	19950616	ES 1992-915456	19920703
HU 70403	A2	19951030	HU 1994-61	19920703



HU 223470	B1	20040728		
PL 171054	B1	19970228	PL 1992-313380	19920703
PL 171094	B1	19970328	PL 1992-313379	19920703
PL 171112	B1	19970328	PL 1992-313381	19920703
PL 171095	B1	19970328	PL 1992-313382	19920703
PL 171333	B1	19970430	PL 1992-302029	19920703
CZ 283602	B6	19980513	CZ 1994-49	19920703
RU 2118316	C1	19980827	RU 1994-15258	19920703
CA 2102697	C	20030930	CA 1992-2102697	19920703
ZA 9205128	A	19930428	ZA 1992-5128	19920709
NO 9304300	A	19931126	NO 1993-4300	19931126
NO 180166	B	19961118		
NO 180166	C	19970226		
FI 105190	B1	20000630	FI 1994-72	19940107
US 5610144	A	19970311	US 1994-175381	19940627
PRIORITY APPLN. INFO.:			FR 1991-8675	A 19910710
			WO 1992-FR626	A 19920703
OTHER SOURCE(S):		MARPAT 120:217658		
GI				



I



II

AB Title compds. [I; Z = CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>, SOO-2, CHOH and R<sub>1</sub> = (substituted)(hetero)aryl; Z = CH<sub>2</sub>, R<sub>1</sub> = H, and R<sub>5</sub> = Ph; Z = CHPh and R<sub>1</sub> = R<sub>5</sub> = H; R<sub>2</sub> = alkoxycarbonyl, CONH<sub>2</sub>, Ph, etc.; R<sub>3</sub> = (substituted) phenylamino, Ph, etc.; R<sub>4</sub> = H, alkyl] were prepd. Thus, L-HSCH<sub>2</sub>CH(NH<sub>2</sub>)CO<sub>2</sub>H was cyclocondensed with PhCHO and the esterified product N-acetylated with Me<sub>3</sub>CO<sub>2</sub>CNHCH<sub>2</sub>CO<sub>2</sub>H to give, after silica chromatog. and deprotection, thiazolidinecarboxylate (2R,4R)-II (III; R = H). The latter was condensed with 3-MeC<sub>6</sub>H<sub>4</sub>NCO to give III (R = CONHC<sub>6</sub>H<sub>4</sub>Me-3). I had IC<sub>50</sub> .ltoreq. 1 mM for inhibition of binding at CCK receptors. Prep. of a chiral HPLC phase for optical resoln. of I is given.

IT 153242-87-6P 153243-31-3P 153243-32-4P  
153244-03-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(prepn. and reaction of, in prepn. of CCK and gastrin receptor ligand)

RN 153242-87-6 CAPLUS

CN 4-Thiazolidinecarboxylic acid, 2-(3-pyridinyl)-3-[[[3-[[2-(trimethylsilyl)ethoxy]carbonyl]phenyl]amino]carbonyl]acetyl]-, 1,1-dimethylethyl ester, (2R-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153243-31-3 CAPLUS

CN L-Proline, 5-(1H-indol-3-yl)-1-[N-[[[3-[[2-(trimethylsilyl)ethoxy]carbonyl]phenyl]amino]carbonyl]glycyl]-, 1,1-dimethylethyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153243-32-4 CAPLUS

CN L-Proline, 5-(1H-indol-3-yl)-1-[N-[[[3-[[2-(trimethylsilyl)ethoxy]carbonyl]phenyl]amino]carbonyl]glycyl]-, 1,1-dimethylethyl ester, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 153244-03-2 CAPLUS

CN D-Proline, N-[[[3-[(phenylmethoxy)carbonyl]phenyl]amino]carbonyl]glycyl-5-

(2-pyridinyl)-, 1,1-dimethylethyl ester, (5S)-rel- (CA INDEX NAME)

Relative stereochemistry.




IT 153241-68-0P 153241-89-5P 153241-90-8P  
153242-19-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as CCK and gastrin receptor ligand)

RN 153241-68-0 CAPLUS

CN 4-Thiazolidinecarboxylic acid, 3-[[[(3-carboxyphenyl)amino]carbonyl]amino]acetyl]-2-(3-pyridinyl)-, 4-(1,1-dimethylethyl) ester, (2R-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153241-89-5 CAPLUS


CN L-Proline, 1-[N-[[[(3-carboxyphenyl)amino]carbonyl]glycyl]-5-(1H-indol-3-yl)-, 2-(1,1-dimethylethyl) ester, cis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 153241-90-8 CAPLUS  
 CN L-Proline, 1-[N-[[ (3-carboxyphenyl)amino]carbonyl]glycyl]-5-(1H-indol-3-yl)-, 2-(1,1-dimethylethyl) ester, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153242-19-4 CAPLUS  
 CN D-Proline, N-[[ (3-carboxyphenyl)amino]carbonyl]glycyl-5-(2-pyridinyl)-, 2-(1,1-dimethylethyl) ester, (5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS  
 RECORD (17 CITINGS)  
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

=>

Executing the logoff script...

=> LOG H

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	114.30	313.84
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-16.40	-16.40

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 11:20:28 ON 21 SEP 2009